About Cambridge Cancer Genomics
Cambridge Cancer Genomics is a company based in Cambridge (United Kingdom) founded in 2015 was acquired by Dante Labs in June 2021.. Cambridge Cancer Genomics has raised $4.62 million across 2 funding rounds from investors including Dante Labs, Refactor Capital and Romulus Capital. The company has 18 employees as of January 31, 2020. Cambridge Cancer Genomics operates in a competitive market with competitors including Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
- Headquarter Cambridge, United Kingdom
- Employees 18 as on 31 Jan, 2020
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Cambridge Cancer Genomics, Inc
- Date of Incorporation 25 Jan, 2017
- Jurisdiction NEW CASTLE COUNTRY, DELAWARE 19808, UNITED STATES
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$4.62 M (USD)
in 2 rounds
-
Latest Funding Round
$4.5 M (USD), Series A
Dec 14, 2018
-
Investors
Dante Labs
& 4 more
-
Employee Count
18
as on Jan 31, 2020
-
Acquired by
Dante Labs
(Jun 23, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Cambridge Cancer Genomics
Cambridge Cancer Genomics has successfully raised a total of $4.62M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $4.5 million completed in December 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $4.5M
-
First Round
First Round
(01 Jun 2017)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2018 | Amount | Series A - Cambridge Cancer Genomics | Valuation | Refactor Capital , Romulus Capital | |
| Jun, 2017 | Amount | Seed - Cambridge Cancer Genomics | Valuation | Y Combinator |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Cambridge Cancer Genomics
Cambridge Cancer Genomics has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Dante Labs, Refactor Capital and Romulus Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed and early-stage investments are made across US and India.
|
Founded Year | Domain | Location | |
|
Early-stage VC firm investing in the US
|
Founded Year | Domain | Location | |
|
AME Cloud Ventures is focused on investing in data-driven technology companies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cambridge Cancer Genomics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Cambridge Cancer Genomics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cambridge Cancer Genomics Comparisons
Competitors of Cambridge Cancer Genomics
Cambridge Cancer Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Digital sequencing technology for cancer detection is developed.
|
|
| domain | founded_year | HQ Location |
Circulating tumor DNA is screened for early cancer detection.
|
|
| domain | founded_year | HQ Location |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| domain | founded_year | HQ Location |
Genomics-based diagnostic tests for cancer are provided.
|
|
| domain | founded_year | HQ Location |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| domain | founded_year | HQ Location |
Health risks are identified through online genetic and diagnostic testing.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cambridge Cancer Genomics
Frequently Asked Questions about Cambridge Cancer Genomics
When was Cambridge Cancer Genomics founded?
Cambridge Cancer Genomics was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Where is Cambridge Cancer Genomics located?
Cambridge Cancer Genomics is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Is Cambridge Cancer Genomics a funded company?
Cambridge Cancer Genomics is a funded company, having raised a total of $4.62M across 2 funding rounds to date. The company's 1st funding round was a Seed of $120K, raised on Jun 01, 2017.
How many employees does Cambridge Cancer Genomics have?
As of Jan 31, 2020, the latest employee count at Cambridge Cancer Genomics is 18.
What does Cambridge Cancer Genomics do?
Founded in 2015 in Cambridge, United Kingdom, Cambridge Cancer Genomics operates in the oncology sector. AI-driven tools are created to support oncologists in precision medicine. Liquid biopsy samples are analyzed through the OncOS platform, where mutations, clinical trial data, and biomarkers are searched to recommend therapeutic strategies. Personalized treatment optimization is facilitated for cancer patients based on these analyses.
Who are the top competitors of Cambridge Cancer Genomics?
Cambridge Cancer Genomics's top competitors include Guardant Health, GRAIL and Foundation Medicine.
Who are Cambridge Cancer Genomics's investors?
Cambridge Cancer Genomics has 5 investors. Key investors include Dante Labs, Refactor Capital, Romulus Capital, AME Cloud Ventures, and Y Combinator.